Published

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychopharmacology (Oxford, England)
Date: 2016-12-01
Source: PubMed
DOI: 10.1177/0269881116675513
PubMed: 27909165

Authors

Griffiths RR Johnson MW Carducci MA Umbricht A Richards WA Richards BD Cosimano MP Klinedinst MA

Watch author

Derived topics and classifications

psilocybin Depression Anxiety End-of-Life Distress Wellbeing Spirituality Mystical Experience Cancer Patients Healthcare Workers Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 20 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement2026-12-01 Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model2026-12-01 Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression2026-11-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12 The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis2026-08-01 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial2026-07-30 Longitudinal neural and psychological changes following psilocybin under compassion imagery priming2026-07-22 Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis2026-07-20 Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder2026-07-16 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions2026-07-03 Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders2026-07-01 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats2026-07-01 Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”2026-06-30 Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex2026-06-28 DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish2026-06-18 Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation2026-06-03 Psilocybin: Chemical Foundations and Emerging Therapeutic Potential2026-06-01 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial2026-06-01